TSHA has 36-month beta value of 0.38. Analysts have mixed views on the stock, with 9 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TSHA is 158.49M, and currently, short sellers hold a 13.03% ratio of that float. The average trading volume of TSHA on October 22, 2024 was 1.45M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TSHA) stock’s latest price update
Taysha Gene Therapies Inc (NASDAQ: TSHA)’s stock price has plunge by -4.70relation to previous closing price of 2.02. Nevertheless, the company has seen a -1.28% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-22 that Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions
TSHA’s Market Performance
Taysha Gene Therapies Inc (TSHA) has experienced a -1.28% fall in stock performance for the past week, with a -5.17% drop in the past month, and a -14.06% drop in the past quarter. The volatility ratio for the week is 3.78%, and the volatility levels for the past 30 days are at 4.22% for TSHA. The simple moving average for the last 20 days is -4.41% for TSHA stock, with a simple moving average of -19.12% for the last 200 days.
Analysts’ Opinion of TSHA
Many brokerage firms have already submitted their reports for TSHA stocks, with BMO Capital Markets repeating the rating for TSHA by listing it as a “Outperform.” The predicted price for TSHA in the upcoming period, according to BMO Capital Markets is $5 based on the research report published on June 27, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see TSHA reach a price target of $9. The rating they have provided for TSHA stocks is “Overweight” according to the report published on April 09th, 2024.
Jefferies gave a rating of “Hold” to TSHA, setting the target price at $1.50 in the report published on February 01st of the previous year.
TSHA Trading at -9.20% from the 50-Day Moving Average
After a stumble in the market that brought TSHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.44% of loss for the given period.
Volatility was left at 4.22%, however, over the last 30 days, the volatility rate increased by 3.78%, as shares sank -6.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.15% lower at present.
During the last 5 trading sessions, TSHA fell by -0.77%, which changed the moving average for the period of 200-days by +8.71% in comparison to the 20-day moving average, which settled at $2.01. In addition, Taysha Gene Therapies Inc saw 8.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSHA starting from Manning Paul B, who purchase 1,333,333 shares at the price of $2.25 back on Jun 27 ’24. After this action, Manning Paul B now owns 1,333,333 shares of Taysha Gene Therapies Inc, valued at $2,999,999 using the latest closing price.
Manning Paul B, the 10% Owner of Taysha Gene Therapies Inc, purchase 100,000 shares at $1.63 during a trade that took place back on Nov 17 ’23, which means that Manning Paul B is holding 16,566,667 shares at $163,000 based on the most recent closing price.
Stock Fundamentals for TSHA
Current profitability levels for the company are sitting at:
- -6.03 for the present operating margin
- 0.9 for the gross margin
The net margin for Taysha Gene Therapies Inc stands at -8.88. The total capital return value is set at -0.47. Equity return is now at value -318.69, with -81.11 for asset returns.
Based on Taysha Gene Therapies Inc (TSHA), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -1.9. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is 110.65.
Currently, EBITDA for the company is -70.0 million with net debt to EBITDA at 1.51. When we switch over and look at the enterprise to sales, we see a ratio of 21.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.20.
Conclusion
To put it simply, Taysha Gene Therapies Inc (TSHA) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
